Stock Track | Amphastar Pharmaceuticals Misses Q3 Earnings Estimates, Stock Plunges

Stock Track11-07

Amphastar Pharmaceuticals Inc. (AMPH) saw its stock price plunge over 10% in after-hours trading on November 6th, following the release of its third-quarter 2024 financial results. The company missed analysts' expectations for both revenue and earnings, citing higher costs and inventory-related charges.

For the quarter ended September 30, 2024, Amphastar reported revenue of $191.21 million, up 5.9% year-over-year but falling short of the consensus estimate of $194.69 million. The company's adjusted earnings per share (EPS) came in at $0.96, missing the consensus estimate of $1.01.

The revenue growth was driven by increased sales of key products, including BAQSIMI, a ready-to-use glucagon injection for the treatment of severe hypoglycemia, Primatene MIST, an over-the-counter asthma inhaler, and epinephrine. However, these gains were partially offset by declines in sales of glucagon, enoxaparin, and naloxone.

On the profitability front, Amphastar faced higher labor costs, increased component costs, and charges related to adjusting inventory and purchase commitments to their net realizable value. These factors weighed on the company's gross margin, which contracted to 53.3% from 60% in the year-ago quarter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1112100997?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 13:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112100997","market":"us","top_or_hot":-1,"title":"Stock Track | Amphastar Pharmaceuticals Misses Q3 Earnings Estimates, Stock Plunges","media":"Stock Track","content":"<p>Amphastar Pharmaceuticals Inc. (AMPH) saw its stock price plunge over 10% in after-hours trading on November 6th, following the release of its third-quarter 2024 financial results. The company missed analysts' expectations for both revenue and earnings, citing higher costs and inventory-related charges.</p>\n\n<p>For the quarter ended September 30, 2024, Amphastar reported revenue of $191.21 million, up 5.9% year-over-year but falling short of the consensus estimate of $194.69 million. The company's adjusted earnings per share (EPS) came in at $0.96, missing the consensus estimate of $1.01.</p>\n\n<p>The revenue growth was driven by increased sales of key products, including BAQSIMI, a ready-to-use glucagon injection for the treatment of severe hypoglycemia, Primatene MIST, an over-the-counter asthma inhaler, and epinephrine. However, these gains were partially offset by declines in sales of glucagon, enoxaparin, and naloxone.</p>\n\n<p>On the profitability front, Amphastar faced higher labor costs, increased component costs, and charges related to adjusting inventory and purchase commitments to their net realizable value. These factors weighed on the company's gross margin, which contracted to 53.3% from 60% in the year-ago quarter.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Amphastar Pharmaceuticals Misses Q3 Earnings Estimates, Stock Plunges</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Amphastar Pharmaceuticals Misses Q3 Earnings Estimates, Stock Plunges\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-07 13:13 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amphastar Pharmaceuticals Inc. (AMPH) saw its stock price plunge over 10% in after-hours trading on November 6th, following the release of its third-quarter 2024 financial results. The company missed ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMPH","symbol_name":"Amphastar Pharmaceuticals","start_time":0,"source_url":"","article_id":"1112100997","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112100997","pubTimestamp":1730956405,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Amphastar Pharmaceuticals Inc.  saw its stock price plunge over 10% in after-hours trading on November 6th, following the release of its third-quarter 2024 financial results. The company missed analysts' expectations for both revenue and earnings, citing higher costs and inventory-related charges.For the quarter ended September 30, 2024, Amphastar reported revenue of $191.21 million, up 5.9% year-over-year but falling short of the consensus estimate of $194.69 million. The company's adjusted ear","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMPH":"Amphastar Pharmaceuticals"},"translate_title":"股票追踪Amphastar Pharmaceuticals第三季度盈利预期未达预期，股价暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMPH":1},"content_text":"Amphastar Pharmaceuticals Inc. (AMPH) saw its stock price plunge over 10% in after-hours trading on November 6th, following the release of its third-quarter 2024 financial results. The company missed analysts' expectations for both revenue and earnings, citing higher costs and inventory-related charges.\nFor the quarter ended September 30, 2024, Amphastar reported revenue of $191.21 million, up 5.9% year-over-year but falling short of the consensus estimate of $194.69 million. The company's adjusted earnings per share (EPS) came in at $0.96, missing the consensus estimate of $1.01.\nThe revenue growth was driven by increased sales of key products, including BAQSIMI, a ready-to-use glucagon injection for the treatment of severe hypoglycemia, Primatene MIST, an over-the-counter asthma inhaler, and epinephrine. However, these gains were partially offset by declines in sales of glucagon, enoxaparin, and naloxone.\nOn the profitability front, Amphastar faced higher labor costs, increased component costs, and charges related to adjusting inventory and purchase commitments to their net realizable value. These factors weighed on the company's gross margin, which contracted to 53.3% from 60% in the year-ago quarter.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1112100997"}